Ocugen

Ocugen

Ocugen

Ocugen is a biotechnology company focused on developing novel biologicals targeting unmet medical needs in treating complex eye diseases including dry agerelated macular degeneration (dry AMD), retinitis pigmentosa (RP) and wet agerelated macular degenera
Raised
$13.5M
Follow us
Alexa global traffic share
Latest funding
$7,500,000
Venture capital (Series B) - 2017
John Zhang Frank Leo Lancaster Group +1
$6,000,000
Venture capital (Series A) - 2016
EB5 Life Sciences
Team Size
1–10
Employees
Pulse 2.0

Ocugen (OCGN) Stock Price: $4.50 Target And Overweight Rating

Pulse 2.0

Ocugen (OCGN) Stock: $6 Price Target And Buy Rating

Pulse 2.0

Ocugen (OCGN) Stock: Why The Price Jumped Up Over 8% Today

Pulse 2.0

Ocugen (OCGN) Stock: Why The Price Increased Today

Pulse 2.0

Ocugen (OCGN) Stock: Why Its Trending Today

Pulse 2.0

Ocugen (OCGN) Stock: Why Its Trending Today

Pulse 2.0

Ocugen (OCGN) Stock: Why Its Surging Today

Pulse 2.0

Ocugen (OCGN) Stock: Why The Price Substantially Increased Today

Pulse 2.0

Ocugen (OCGN) Stock: Why The Price Went Up Today

Pulse 2.0

Ocugen Stock (OCGN): Why The Price Jumped Today

Pulse 2.0

Ocugen Stock (OCGN): Why The Price Jumped Today

Pulse 2.0

Ocugen Stock (OCGN): Why The Price Jumped Today

Pulse 2.0

Ocugen Stock (OCGN): Why The Price Fell Today

Pulse 2.0

Ocugen (OCGN) Stock: Why The Price Jumped Today

Pulse 2.0

Ocugen (OCGN) Stock: Why The Price Increased Yesterday

Pulse 2.0

Ocugen Stock Price Increased Over 3% Pre-Market: Why It Happened

Pulse 2.0

Ocugen Stock Price Increased 8.5%: Why It Happened

Pulse 2.0

Ocugen (OCGN) Stock Price Increases 173.88%: Why It Happened

Technical.ly

Funding news about Ocugen

Funding
$6,000,000 Venture capital (Series A)
prnewswire , biospace

Ocugen Closes $6 Million in Series A Funding